4-((S)-2-amino-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester | 1019929-53-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-((S)-2-amino-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester
• 英文别名: butyl 4-[(2S)-2-amino-3-methylbutanoyl]piperazine-1-carboxylate
• CAS: 1019929-53-3
• 化学式: C₁₄H₂₇N₃O₃
• 分子量: 285.387
• InChiKey: KMEPVAXHVLXJKM-LBPRGKRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  75.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((S)-2-amino-3-methyl-butyryl)-piperazine-1-carboxylic acid butyl ester 、 2-苯基-1,3-噻唑-4-甲酸 在 乙酸乙酯 作用下， 以 二氯甲烷 为溶剂， 生成 4-{(S)-3-methyl-2-[(2-phenyl-thiazole-4-carbonyl)-amino]-butyryl}-piperazine-1-carboxylic acid butyl ester
  参考文献：
  名称：

  THIAZOLE DERIVATIVES AND THEIR USE AS P2Y12 RECEPTOR ANTAGONISTS

  摘要：

  本发明涉及式I的噻唑衍生物及其作为P2Y12受体拮抗剂在治疗和/或预防外周血管、内脏、肝脏和肾脏血管、心血管和脑血管疾病或与血小板聚集有关的状况，包括哺乳动物中的血栓形成。

  公开号：

  US20120053149A1

文献信息

• 2-AMINOCARBONYL-PYRIDINE DERIVATIVES
  申请人：Caroff Eva

  公开号：US20100035895A1

  公开（公告）日：2010-02-11

  The present invention relates to 2-aminocarbonyl-pyridine derivatives of Formula (I) and their use as P2Y 12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis.

  本发明涉及公式（I）的2-氨基羰基吡啶衍生物及其在治疗和/或预防与血小板聚集相关的周围血管、内脏、肝脏和肾脏血管、心血管和脑血管疾病或病况中作为P2Y12受体拮抗剂的用途，包括血栓形成。
• Thiazole derivatives and their use as P2Y12 receptor antagonists
  申请人：Caroff Eva

  公开号：US08664203B2

  公开（公告）日：2014-03-04

  The present invention relates to thiazole derivatives of formula I and their use as P2Y12 receptor antagonists in the treatment and/or prevention of peripheral vascular, of visceral-, hepatic- and renal-vascular, of cardiovascular and of cerebrovascular diseases or conditions associated with platelet aggregation, including thrombosis in humans and other mammals.

  本发明涉及式I的噻唑衍生物及其在治疗和/或预防与血小板聚集相关的外周血管、内脏、肝脏和肾脏血管、心血管和脑血管疾病或情况，包括哺乳动物中的血栓形成中作为P2Y12受体拮抗剂的用途。
• 4-((<i>R</i>)-2-{[6-((<i>S</i>)-3-Methoxypyrrolidin-1-yl)-2-phenylpyrimidine-4-carbonyl]amino}-3-phosphonopropionyl)piperazine-1-carboxylic Acid Butyl Ester (ACT-246475) and Its Prodrug (ACT-281959), a Novel P2Y₁₂ Receptor Antagonist with a Wider Therapeutic Window in the Rat Than Clopidogrel
  作者：Eva Caroff、Francis Hubler、Emmanuel Meyer、Dorte Renneberg、Carmela Gnerre、Alexander Treiber、Markus Rey、Patrick Hess、Beat Steiner、Kurt Hilpert、Markus A. Riederer

  DOI：10.1021/acs.jmedchem.5b00933

  日期：2015.12.10

  Recent post hoc analyses of several clinical trials with P2Y(12) antagonists showed the need for new molecules being fully efficacious as antiplatelet agents and having a reduced propensity to cause major bleeding. We have previously reported the discovery of the 2-phenylpyrimidine-4-carboxamide analogs as P2Y(12) antagonists with nanomolar potency in the disease-relevant platelet aggregation assay in human plasma. Herein we present the optimization steps that led to the discovery of clinical candidate ACT-246475 (30d). The key step was the replacement of the carboxylic acid functionality by a phosphonic acid group which delivered the most potent molecules of the program. In addition, low in vivo clearance in rat and dog was achieved for the first time. Since the bioavailability of 30d was low in rat and dog, we developed the bis((isopropoxycarbonyl)oxy)methyl ester prodrug (ACT-281959, 45). Compound 30d showed efficacy in the rat ferric chloride thrombosis model when administered intravenously as parent or orally as its prodrug 45. Moreover, 30d displays a wider therapeutic window as compared to clopidogrel in the rat surgical blood loss model.
• EP2081903B1
  申请人：——

  公开号：EP2081903B1

  公开（公告）日：2014-05-07
• US8093250B2
  申请人：——

  公开号：US8093250B2

  公开（公告）日：2012-01-10